Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

36.16
-0.2500-0.69%
Post-market: 36.440.2800+0.77%19:30 EDT
Volume:2.27M
Turnover:81.23M
Market Cap:3.49B
PE:-7.68
High:36.41
Open:36.13
Low:35.06
Close:36.41
52wk High:72.66
52wk Low:35.06
Shares:96.64M
Float Shares:95.45M
Volume Ratio:0.94
T/O Rate:2.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7061
EPS(LYR):-4.3646
ROE:-43.62%
ROA:-28.02%
PB:2.81
PE(LYR):-8.28

Loading ...

Xenon Stock Craters on Drug Trial Setback. Its Failure Could be This Rival's Gain.

Dow Jones
·
Sep 18

Goldman Sachs Sticks to Its Buy Rating for Xenon (XENE)

TIPRANKS
·
Sep 18

【US Pre-Market】US Stock Futures Mixed on Triple Witching; Optical Communication, Storage, and Crypto Stocks Gain as WTI Crude Plunges Over 5%

TradingKey
·
Sep 18

Top Premarket Decliners

MT Newswires Live
·
Sep 18

U.S. Stocks on the MOVE-Netflix, Etsy, Viant Technology

Reuters
·
Sep 18

Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword

Dow Jones
·
Sep 18

S&P 500 Futures Rise in Premarket Trading; Xenon Pharmaceuticals, Icon PLC Lag

Dow Jones
·
Sep 18

Xenon Pharmaceuticals Price Target Cut to $90.00/Share from $97.00 by Baird

Dow Jones
·
Sep 18

Xenon Pharmaceuticals price target lowered to $90 from $97 at Baird

TIPRANKS
·
Sep 18

Xenon Pharmaceuticals Inc. : Deutsche Bank Cuts to Hold from Buy; Cuts Target Price to $46 from $90

THOMSON REUTERS
·
Sep 18

Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB)

TIPRANKS
·
Sep 18

Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold From Buy, Adjusts PT to $46 From $90

MT Newswires Live
·
Sep 18

Xenon Pharmaceuticals Shares Fall 27,5% Premarket After Co Pauses New Enrollment in Depression Drug Trials

THOMSON REUTERS
·
Sep 18

Xenon Pharmaceuticals Inc. : RBC Cuts Target Price to $70 from $81

THOMSON REUTERS
·
Sep 18

Stocks to Watch: Xenon Pharmaceuticals, Ultragenyx Pharmaceutical, BRT Apartments

Dow Jones
·
Sep 18

Xenon Pauses New Enrollment in Depression, Bipolar Disorder Trials over Side-Effect Concerns

Reuters
·
Sep 18

Xenon Pharma Plunges After Pausing Trial Enrollment Due to Side Effects

Reuters
·
Sep 18

Xenon Submits FDA NDA for Azetukalner in Focal Seizures

Reuters
·
Sep 18

Xenon Pharmaceuticals - Initiates Temporary Pause of Enrollment in Ongoing Psychiatry Studies

THOMSON REUTERS
·
Sep 18

Xenon Announces Azetukalner Nda Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

THOMSON REUTERS
·
Sep 18